奥马珠单抗治疗过敏性哮喘的研究进展
Research Progress of Omalizumab in the Treatment of Allergic Asthma
DOI: 10.12677/ACM.2021.112099, PDF,   
作者: 马晓伟：山东大学，山东 济南；陈 娜：威海市中医院，山东 威海；王智远, 张才擎*：山东省第二人民医院，山东 济南
关键词: 过敏性哮喘；IgE；奥马珠单抗；Allergic Asthma； IgE； Omalizumab
摘要: 奥马珠单抗(omalizumab)是一种人源化的抗人免疫球蛋白E单克隆抗体，通过阻止IgE与其受体相结合，抑制IgE介导的肥大细胞和嗜碱性粒细胞的活化和脱颗粒，进而有效减轻甚至避免其诱导的哮喘发作。本文综述了奥马珠单抗治疗过敏性哮喘的作用机制和临床应用现状，分析了其安全性与耐受性，并探讨了其应用前景。
Abstract: Omalizumab is a humanized monoclonal antibody against human immunoglobulin E that effectively reduces or even prevents IgE from binding to its receptor, inhibiting IgE mediated activation and degranulation of mast cells and basophil cells, and thereby effectively alleviating or even avoiding asthma attacks induced by it. In this paper, the mechanism of action and clinical application of omalizumab in the treatment of allergic asthma were reviewed, its safety and tolerance were analyzed, and its application prospect was discussed.
文章引用：马晓伟, 陈娜, 王智远, 张才擎. 奥马珠单抗治疗过敏性哮喘的研究进展[J]. 临床医学进展, 2021, 11(2): 682-689. https://doi.org/10.12677/ACM.2021.112099

参考文献

[1] (2014) The Global Asthma Report 2014. Global Asthma Network, Auckland. http://www.globalasthmareport.org|resources|Global_Asthma_Report_2014
[2] 林江涛. 抗IgE治疗过敏性哮喘的长期有效性和安全性[J]. 中华结核和呼吸杂志, 2016, 39(9): 733-736.
[3] Schatz, M. and Rosenwasser, L. (2014) The Allergic Asthma Phenotype. The Journal of Allergy and Clinical Immunology: In Practice, 2, 645-649. ://doi.org/10.1016/j.jaip.2014.09.004
[4] Pelaia, C., Calabrese, C., Terracciano, R., de Blasio, F., Vatrella, A. and Pelaia, G. (2018) Omalizumab, the First Available Antibody for Biological Treatment of Severe Asthma: More than a Decade of Real-Life Effectiveness. Therapeutic Advances in Respiratory Disease, 12, 1753466618810192. ://doi.org/10.1177/1753466618810192
[5] Ribatti, D. (2016) The Discovery of Immunoglobulin E. Immunology Letters, 171, 1-4. ://doi.org/10.1016/j.imlet.2016.01.001
[6] Mitropoulou, A.N., Ceska, T., Heads, J.T., et al. (2020) Engineering the Fab Fragment of the Anti-IgE Omalizumab to Prevent Fab Crystallization and Permit IgE-Fc Complex Crystallization. Acta Crystallographica Section F: Structural Biology Communications, 76, 116-129. ://doi.org/10.1107/S2053230X20001466
[7] Rath, N., Raje, N. and Rosenwasser, L. (2018) Immunoglobulin E as a Biomarker in Asthma. Immunology and Allergy Clinics of North America, 38, 587-597. ://doi.org/10.1016/j.iac.2018.06.007
[8] Navinés-Ferrer, A., Serrano-Candelas, E., Molina-Molina, G.J. and Martín, M. (2016) IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. Journal of Immunology Research, 2016, Article ID: 8163803. ://doi.org/10.1155/2016/8163803
[9] Anto, J.M., Bousquet, J., Akdis, M., et al. (2017) Mechanisms of the Development of Allergy (MeDALL): Introducing Novel Concepts in Allergy Phenotypes. The Journal of Allergy and Clinical Immunology, 139, 388-399. ://doi.org/10.1016/j.jaci.2016.12.940
[10] Galli, S.J. and Tsai, M. (2012) IgE and Mast Cells in Allergic Disease. Nature Medicine, 18, 693-704. ://doi.org/10.1038/nm.2755
[11] Humbert, M., Bousquet, J., Bachert, C., et al. (2019) IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. The Journal of Allergy and Clinical Immunology: In Practice, 7, 1418-1429. ://doi.org/10.1016/j.jaip.2019.02.030
[12] (2002) Omalizumab: Anti-IgE Monoclonal Antibody E25, E25, Humanised Anti-IgE MAb, IGE 025, Monoclonal Antibody E25, Olizumab, Xolair, rhuMAb-E25. BioDrugs, 16, 380-386. ://doi.org/10.2165/00063030-200216050-00009
[13] Presta, L.G., Lahr, S.J., Shields, R.L., et al. (1993) Humanization of an Antibody Directed against IgE. Journal of Immunology, 151, 2623-2632.
[14] Pelaia, G., Gallelli, L., Renda, T., et al. (2011) Update on Optimal Use of Omalizumab in Management of Asthma. Journal of Asthma and Allergy, 4, 49-59. ://doi.org/10.2147/JAA.S14520
[15] Chang, T.W., Wu, P.C., Hsu, C.L. and Hung, A.F. (2007) Anti-IgE Antibodies for the Treatment of IgE-Mediated Allergic Diseases. Advances in Immunology, 93, 63-119. ://doi.org/10.1016/S0065-2776(06)93002-8
[16] Hochhaus, G., Brookman, L., Fox, H., et al. (2003) Pharmacodynamics of Omalizumab: Implications for Optimised Dosing Strategies and Clinical Efficacy in the Treatment of Allergic Asthma. Current Medical Research and Opinion, 19, 491-498. ://doi.org/10.1185/030079903125002171
[17] Fox, J.A., Hotaling, T.E., Struble, C., Ruppel, J., Bates, D.J. and Schoenhoff, M.B. (1996) Tissue Distribution and Complex Formation with IgE of an Anti-IgE Antibody after Intravenous Administration in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 279, 1000-1008.
[18] Hoshino, M. and Ohtawa, J. (2012) Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma. Respiration, 83, 520-528. ://doi.org/10.1159/000334701
[19] Wright, J.D., Chu, H.M., Huang, C.H., Ma, C., Chang, T.W. and Lim, C. (2015) Structural and Physical Basis for Anti-IgE Therapy. Scientific Reports, 5, Article No. 11581. ://doi.org/10.1038/srep11581
[20] Hendeles, L. and Sorkness, C.A. (2007) Anti-Immunoglobulin E Therapy with Omalizumab for Asthma. Annals of Pharmacotherapy, 41, 1397-1410. ://doi.org/10.1345/aph.1K005
[21] European Medicines Agency (2016) Xolair-Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf
[22] Marcus, P., Practice Management Committee, American College of Chest Physicians (2006) Incorporating Anti-IgE (Omalizumab) Therapy into Pulmonary Medicine Practice: Practice Management Implications. Chest, 129, 466-474. ://doi.org/10.1378/chest.129.2.466
[23] Miller, C.W., Krishnaswamy, N., Johnston, C. and Krishnaswamy, G. (2008) Severe Asthma and the Omalizumab Option. Clinical and Molecular Allergy, 6, 4. ://doi.org/10.1186/1476-7961-6-4
[24] Luu, M., Bardou, M., Bonniaud, P. and Goirand, F. (2016) Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Omalizumab for the Treatment of Asthma. Expert Opinion on Drug Metabolism & Toxicology, 12, 1503-1511. ://doi.org/10.1080/17425255.2016.1248403
[25] 李靖. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018, 41(3): 179-185.
[26] Vignola, A.M., Humbert, M., Bousquet, J., et al. (2004) Efficacy and Tolerability of Anti-Immunoglobulin E Therapy with Omalizumab in Patients with Concomitant Allergic Asthma and Persistent Allergic Rhinitis: SOLAR. Allergy, 59, 709-717. ://doi.org/10.1111/j.1398-9995.2004.00550.x
[27] Humbert, M., Beasley, R., Ayres, J., et al. (2005) Benefits of Omalizumab as Add-On Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled Despite Best Available Therapy (GINA 2002 Step 4 Treatment): INNOVATE. Allergy, 60, 309-316. ://doi.org/10.1111/j.1398-9995.2004.00772.x
[28] Martínez-Moragón, E., Climent, M., Chiner, E., Fernández-Aracil, C., Sánchez-Toril, F. and Lluch-Tortajada, I. (2019) Effectiveness and Pharmacoeconomic Analysis of the Treatment of Severe Asthma with Omalizumab in Clinical Practice. Efectividad y análisis farmacoeconómico del tratamiento del asma grave con omalizumab en la práctica clínica. Farmacia Hospitalaria, 43, 101-109.
[29] Adachi, M., Kozawa, M., Yoshisue, H., et al. (2018) Real-World Safety and Efficacy of Omalizumab in Patients with Severe Allergic Asthma: A Long-Term Post-Marketing Study in Japan. Respiratory Medicine, 141, 56-63. ://doi.org/10.1016/j.rmed.2018.06.021
[30] Al-Ahmad, M., Arifhodzic, N., Nurkic, J., et al. (2018) “Real-Life” Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma. Medical Principles and Practice, 27, 260-266. ://doi.org/10.1159/000487482
[31] Frix, A.N., Schleich, F., Paulus, V., Guissard, F., Henket, M. and Louis, R. (2020) Effectiveness of Omalizumab on Patient Reported Outcomes, Lung Function, and Inflammatory Markers in Severe Allergic Asthma. Biochemical Pharmacology, 179, Article ID: 113944. ://doi.org/10.1016/j.bcp.2020.113944
[32] Pelaia, C., Calabrese, C., Barbuto, S., et al. (2019) Omalizumab Lowers Asthma Exacerbations, Oral Corticosteroid Intake and Blood Eosinophils: Results of a 5-YEAR Single-Centre Observational Study. Pulmonary Pharmacology & Therapeutics, 54, 25-30. ://doi.org/10.1016/j.pupt.2018.11.002
[33] Busse, W.W., Morgan, W.J., Gergen, P.J., et al. (2011) Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. The New England Journal of Medicine, 364, 1005-1015. ://doi.org/10.1056/NEJMoa1009705
[34] Busse, W.W., Humbert, M., Haselkorn, T., et al. (2020) Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents with Moderate-to-Severe Allergic Asthma. Annals of Allergy, Asthma & Immunology, 124, 190-196. ://doi.org/10.1016/j.anai.2019.11.016
[35] Gibson, P.G., Reddel, H., McDonald, V.M., et al. (2016) Effectiveness and Response Predictors of Omalizumab in a Severe Allergic Asthma Population with a High Prevalence of Comorbidities: The Australian Xolair Registry. Internal Medicine Journal, 46, 1054-1062. ://doi.org/10.1111/imj.13166
[36] Ledford, D., Busse, W., Trzaskoma, B., et al. (2017) A Randomized Multicenter Study Evaluating Xolair Persistence of Response after Long-Term Therapy. The Journal of Allergy and Clinical Immunology, 140, 162-169.e2. ://doi.org/10.1016/j.jaci.2016.08.054
[37] Nopp, A., Johansson, S.G., Adédoyin, J., Ankerst, J., Palmqvist, M. and Oman, H. (2010) After 6 Years with Xolair; a 3-Year Withdrawal Follow-Up. Allergy, 65, 56-60. ://doi.org/10.1111/j.1398-9995.2009.02144.x
[38] Kupryś-Lipińska, I. and Kuna, P. (2014) Loss of Asthma Control after Cessation of Omalizumab Treatment: Real Life Data. Postępy Dermatologii i Alergologii, 31, 1-5. ://doi.org/10.5114/pdia.2014.40553
[39] Cox, L., Platts-Mills, T.A., Finegold, I., et al. (2007) American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on Omalizumab-Associated Anaphylaxis. The Journal of Allergy and Clinical Immunology, 120, 1373-1377. ://doi.org/10.1016/j.jaci.2007.09.032
[40] Di Bona, D., Fiorino, I., Taurino, M., et al. (2017) Long-Term “Real-Life” Safety of Omalizumab in Patients with Severe Uncontrolled Asthma: A Nine-Year Study. Respiratory Medicine, 130, 55-60. ://doi.org/10.1016/j.rmed.2017.07.013
[41] Schreiber, J., Schwab Sauerbeck, I. and Mailänder, C. (2020) The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study. Advances in Therapy, 37, 353-363. ://doi.org/10.1007/s12325-019-01135-w
[42] Rodrigo, G.J., Neffen, H. and Castro-Rodriguez, J.A. (2011) Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-On Therapy to Corticosteroids for Children and Adults with Asthma: A Systematic Review. Chest, 139, 28-35. ://doi.org/10.1378/chest.10-1194
[43] Iribarren, C., Rahmaoui, A., Long, A.A., et al. (2017) Cardiovascular and Cerebrovascular Events among Patients Receiving Omalizumab: Results from EXCELS, a Prospective Cohort Study in Moderate to Severe Asthma. The Journal of Allergy and Clinical Immunology, 139, 1489-1495.e5. ://doi.org/10.1016/j.jaci.2016.07.038
[44] Long, A., Rahmaoui, A., Rothman, K.J., et al. (2014) Incidence of Malignancy in Patients with Moderate-to-Severe Asthma Treated with or without Omalizumab. The Journal of Allergy and Clinical Immunology, 134, 560-567.e4. ://doi.org/10.1016/j.jaci.2014.02.007
[45] Cruz, A.A., Lima, F., Sarinho, E., et al. (2007) Safety of Anti-Immunoglobulin E Therapy with Omalizumab in Allergic Patients at Risk of Geohelminth Infection. Clinical & Experimental Allergy, 37, 197-207. ://doi.org/10.1111/j.1365-2222.2007.02650.x

为你推荐